{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:00:58Z","timestamp":1794621658715,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The CGRP pathway targeting antibody fremanezumab is indicated for prevention of migraine in adults with \u22654 migraine days\/month. To address the limited availability in real-world long-term data, the FINESSE study was initiated to provide real-world evidence of long-term effectiveness of fremanezumab in clinical practice in an unselected migraine patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FINESSE was a non-interventional, prospective, multicentre, two-country (Germany, Austria) study observing migraine patients receiving fremanezumab over 24\u2009months in clinical routine. The primary endpoint was the proportion of patients reaching \u226550% reduction in the monthly average number of migraine days (MMD) during the 6-month period following fremanezumab initiation. Secondary endpoints included changes from baseline in MMD, MIDAS and HIT-6 scores, and use of concomitant acute migraine medication. Exploratory endpoints comprised assessment of number and classes of concomitant preventive and acute migraine medications, and reduction in migraine severity. All secondary and exploratory outcomes were evaluated at multiple timepoints over the 24-month observation period. Safety data were obtained based on documentation of adverse events reported in normal clinical practice. Data analysis was performed using descriptive and, for comparisons to baseline, inferential statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data of 1016 patients (88.7% female; mean age 45.7 (SD 12.4); 55% episodic migraine; 45% chronic migraine) were evaluable in the full analysis set. Out of 987 patients in the primary endpoint set, the proportion of responders with a\u2009\u2265\u200950% MMD reduction during the 6-month period following fremanezumab initiation was 52.8% in all patients, 57.0% in episodic and 47.8% in chronic migraine patients. Further benefit was observed in terms of clinically meaningful MMD reductions from baseline, decrease in the use of concomitant acute medication, migraine severity, and improvements in disability scores, which were sustained over the 24-month observation period. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term fremanezumab treatment was associated with rapid, substantial and sustained improvement in both episodic and chronic migraine in a high proportion of patients in a real-world setting throughout the 24-month observation period. Real-world-data on tolerability corroborate the expected favourable safety profile of fremanezumab demonstrated in the pivotal clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The FINESSE study was retrospectively registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606) on December 8, 2021, and previously registered at Paul-Ehrlich-Institut (Federal Institute for Vaccines and biomedicines) on November 11, 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02259-x","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T03:03:59Z","timestamp":1766459039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine \u2013 24-months results from the prospective non-interventional FINESSE study"],"prefix":"10.1186","volume":"27","author":[{"given":"Andreas","family":"Straube","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"10283","key":"2259_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/s0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","journal-title":"Lancet"},{"key":"2259_CR2","doi-asserted-by":"crossref","unstructured":"Diener HC, F\u00f6rderreuther S, Kropp P, Reuter U et al Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie, 2025, DGN und DMKG. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: https:\/\/doi.org\/www.dgn.org\/leitlinien Accessed 21 Oct 2025","DOI":"10.1007\/s42451-025-00829-6"},{"issue":"1","key":"2259_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"5","key":"2259_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"issue":"4","key":"2259_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"issue":"5922","key":"2259_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod JJ, Amara SG et al (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304(5922):129\u2013135. https:\/\/doi.org\/10.1038\/304129a0","journal-title":"Nature"},{"issue":"1","key":"2259_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"issue":"Suppl, 2","key":"2259_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/head.13081","volume":"57","author":"L Edvinsson","year":"2017","unstructured":"Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57(Suppl, 2):47\u201355. https:\/\/doi.org\/10.1111\/head.13081","journal-title":"Headache"},{"issue":"2","key":"2259_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/pmt-2020-0030","volume":"11","author":"LM Frerichs","year":"2021","unstructured":"Frerichs LM, Friedman DI (2021) Galcanezumab for the prevention of migraine. Pain Manag 11(2):101\u2013112. https:\/\/doi.org\/10.2217\/pmt-2020-0030","journal-title":"Pain Manag"},{"issue":"22","key":"2259_CR10","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"11","key":"2259_CR11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/1440-1681.13700","volume":"49","author":"YMT Siahaan","year":"2022","unstructured":"Siahaan YMT, Hartoyo V, Hariyanto TI (2022) Efficacy and safety of eptinezumab as preventive treatment for episodic\/chronic migraine: a systematic review and meta-analysis. Clin Exp Pharmacol Physiol 49(11):1156\u20131168. https:\/\/doi.org\/10.1111\/1440-1681.13700","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"52","key":"2259_CR12","doi-asserted-by":"publisher","first-page":"e18483","DOI":"10.1097\/md.0000000000018483","volume":"98","author":"C Zhu","year":"2019","unstructured":"Zhu C, Guan J, Xiao H, Luo W, Tong R (2019) Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Med (Baltimore) 98(52):e18483. https:\/\/doi.org\/10.1097\/md.0000000000018483","journal-title":"Med (baltim)"},{"issue":"3","key":"2259_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/wco.0000000000000438","volume":"30","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30(3):272\u2013280. https:\/\/doi.org\/10.1097\/wco.0000000000000438","journal-title":"Curr Opin Neurol"},{"issue":"11\u201312","key":"2259_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1177\/03331024211018137","volume":"41","author":"F Frank","year":"2021","unstructured":"Frank F, Ulmer H, Sidoroff V, Broessner G (2021) CGRP-antibodies, topiramate and botulinum toxin type a in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia 41(11\u201312):1222\u20131239. https:\/\/doi.org\/10.1177\/03331024211018137","journal-title":"Cephalalgia"},{"issue":"8","key":"2259_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J et al (2021) Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs 35(8):805\u2013820. https:\/\/doi.org\/10.1007\/s40263-021-00834-9","journal-title":"CNS Drugs"},{"issue":"1","key":"2259_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M et al (2023) Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. J Headache Pain 24(1):144. https:\/\/doi.org\/10.1186\/s10194-023-01682-2","journal-title":"J Headache Pain"},{"issue":"8","key":"2259_CR17","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","volume":"260","author":"DC Buse","year":"2013","unstructured":"Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260(8):1960\u20131969. https:\/\/doi.org\/10.1007\/s00415-012-6725-x","journal-title":"J Neurol"},{"issue":"1","key":"2259_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF et al (2022) A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain 23(1):54. https:\/\/doi.org\/10.1186\/s10194-022-01413-z","journal-title":"J Headache Pain"},{"key":"2259_CR19","unstructured":"European Medicines Agency (2019) Ajovy Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf. Accessed 3 Sep 2025"},{"issue":"19","key":"2259_CR20","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. Jama 319(19):1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"Jama"},{"issue":"5","key":"2259_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102419885905","volume":"40","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Kudrow D, Yeung PP et al (2020) Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine. Cephalalgia 40(5):470\u2013477. https:\/\/doi.org\/10.1177\/0333102419885905","journal-title":"Cephalalgia"},{"issue":"10203","key":"2259_CR22","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/s0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040. https:\/\/doi.org\/10.1016\/s0140-6736(19)31946-4","journal-title":"Lancet"},{"issue":"3","key":"2259_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40120-024-00591-z","volume":"13","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Egeo G, Proietti S et al (2024) Assessing the long-term (48-week) effectiveness, safety, and tolerability of fremanezumab in migraine in real life: insights from the multicenter, prospective, FRIEND3 study. Neurol Ther 13(3):611\u2013624. https:\/\/doi.org\/10.1007\/s40120-024-00591-z","journal-title":"Neurol Ther"},{"issue":"11","key":"2259_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui S, Daisuke D, Miyahara J et al (2024) Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Med 25(11):664\u2013670. https:\/\/doi.org\/10.1093\/pm\/pnae050","journal-title":"Pain Med"},{"issue":"1","key":"2259_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/head.14788","volume":"65","author":"R Ornello","year":"2025","unstructured":"Ornello R, Baldini F, Onofri A et al (2025) Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-a real-world study. Headache 65(1):61\u201367. https:\/\/doi.org\/10.1111\/head.14788","journal-title":"Headache"},{"issue":"6","key":"2259_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s11096-024-01758-2","volume":"46","author":"E Pons-Fuster","year":"2024","unstructured":"Pons-Fuster E, Lozano-Caballero O, Mart\u00edn-Balbuena S et al (2024) Anti\u2011CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. Int J Clin Pharm 46(6):1317\u20131326. https:\/\/doi.org\/10.1007\/s11096-024-01758-2","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"2259_CR27","doi-asserted-by":"publisher","first-page":"e3631","DOI":"10.1002\/brb3.3631","volume":"14","author":"J Tudela-Tomas","year":"2024","unstructured":"Tudela-Tomas J, Ramos-Guerrero RM, Rodriguez-Mateos ME (2024) Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: a real-life study. Brain Behav 14(7):e3631. https:\/\/doi.org\/10.1002\/brb3.3631","journal-title":"Brain Behav"},{"issue":"3","key":"2259_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0005-7967(94)00075-u","volume":"33","author":"PF Lovibond","year":"1995","unstructured":"Lovibond PF, Lovibond SH (1995) The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the beck Depression and Anxiety inventories. Behav Res Ther 33(3):335\u2013343. https:\/\/doi.org\/10.1016\/0005-7967(94)00075-u","journal-title":"Behav Res Ther"},{"issue":"2","key":"2259_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19(2):107\u2013114; discussion 174. doi: https:\/\/doi.org\/10.1046\/j.1468-2982.1999.019002107.x","journal-title":"Cephalalgia"},{"issue":"5","key":"2259_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/wnl.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J et al (1999) An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology 53(5):988\u2013994. https:\/\/doi.org\/10.1212\/wnl.53.5.988","journal-title":"Neurology"},{"issue":"3","key":"2259_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the headache impact test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia 31(3):357\u2013367. https:\/\/doi.org\/10.1177\/0333102410379890","journal-title":"Cephalalgia"},{"issue":"1","key":"2259_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"2259_CR33","first-page":"i-xii, 1","volume":"894","author":"World Health Organization (WHO)","year":"2000","unstructured":"World Health Organization (WHO) (2000) Obesity: preventing and managing the global epidemic. Report of a who consultation. World Health Organ Tech Rep Ser 894:i-xii, 1\u2013253","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"6","key":"2259_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00482-015-0019-z","volume":"29","author":"P Nilges","year":"2015","unstructured":"Nilges P, Essau C (2015) Depression, anxiety and stress scales: DASS-A screening procedure not only for pain patients. Schmerz 29(6):649\u2013657. https:\/\/doi.org\/10.1007\/s00482-015-0019-z","journal-title":"Schmerz"},{"issue":"1","key":"2259_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2023) Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. J Headache Pain 24(1):30. https:\/\/doi.org\/10.1186\/s10194-023-01561-w","journal-title":"J Headache Pain"},{"issue":"11","key":"2259_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081\u20131090. https:\/\/doi.org\/10.1016\/s1474-4422(15)00249-5","journal-title":"Lancet Neurol"},{"issue":"11","key":"2259_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091\u20131100. https:\/\/doi.org\/10.1016\/s1474-4422(15)00245-8","journal-title":"Lancet Neurol"},{"issue":"18","key":"2259_CR38","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/wnl.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95(18):e2487\u2013e2499. https:\/\/doi.org\/10.1212\/wnl.0000000000010600","journal-title":"Neurology"},{"issue":"1","key":"2259_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ et al (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the halo CM study. J Headache Pain 21(1):114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"issue":"1","key":"2259_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N et al (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32(1):6\u201338. https:\/\/doi.org\/10.1177\/0333102411417901","journal-title":"Cephalalgia"},{"issue":"1","key":"2259_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-023-01593-2","volume":"24","author":"A Straube","year":"2023","unstructured":"Straube A, Broessner G, Gaul C et al (2023) Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study. J Headache Pain 24(1):59. https:\/\/doi.org\/10.1186\/s10194-023-01593-2","journal-title":"J Headache Pain"},{"issue":"2","key":"2259_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00415-025-12911-w","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Torelli P et al (2025) Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study. J Neurol 272(2):170. https:\/\/doi.org\/10.1007\/s00415-025-12911-w","journal-title":"J Neurol"},{"issue":"11","key":"2259_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/wnl.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2023) Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology 101(11):482\u2013488. https:\/\/doi.org\/10.1212\/wnl.0000000000207292","journal-title":"Neurology"},{"issue":"5","key":"2259_CR44","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2024) Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol 271(5):2434\u20132443. https:\/\/doi.org\/10.1007\/s00415-023-12103-4","journal-title":"J Neurol"},{"issue":"1","key":"2259_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"4","key":"2259_CR46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s00115-022-01403-1","volume":"94","author":"G Go\u00dfrau","year":"2023","unstructured":"Go\u00dfrau G, F\u00f6rderreuther S, Ruscheweyh R et al (2023) Consensus statement of the migraine and headache societies (DMKG, \u00d6KSG, and SKG) on the duration of pharmacological migraine prophylaxis. Nervenarzt 94(4):306\u2013317. https:\/\/doi.org\/10.1007\/s00115-022-01403-1","journal-title":"Nervenarzt"},{"issue":"12","key":"2259_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-023-01050-3","volume":"37","author":"V Caponnetto","year":"2023","unstructured":"Caponnetto V, Russo A, Silvestro M et al (2023) Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine: a prospective multicenter cohort study. CNS Drugs 37(12):1069\u20131080. https:\/\/doi.org\/10.1007\/s40263-023-01050-3","journal-title":"CNS Drugs"},{"issue":"9","key":"2259_CR48","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","volume":"34","author":"T Vu","year":"2017","unstructured":"Vu T, Ma P, Chen JS et al (2017) Pharmacokinetic-pharmacodynamic relationship of Erenumab (AMG 334) and capsaicin-induced dermal Blood Flow in healthy and migraine subjects. Pharm Res 34(9):1784\u20131795. https:\/\/doi.org\/10.1007\/s11095-017-2183-6","journal-title":"Pharm Res"},{"issue":"19","key":"2259_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/wnl.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG et al (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology 99(19):841\u2013853. https:\/\/doi.org\/10.1212\/wnl.0000000000201332","journal-title":"Neurology"},{"key":"2259_CR50","doi-asserted-by":"publisher","unstructured":"Orlando B, Egeo G, Aurilia C, Fiorentini G, Barbanti P (2024) Calcitonin gene-related peptide monoclonal antibodies: key lessons from real-world evidence. Brain Sci 14(9). https:\/\/doi.org\/10.3390\/brainsci14090948","DOI":"10.3390\/brainsci14090948"},{"issue":"6","key":"2259_CR51","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s40122-024-00658-7","volume":"13","author":"C Gaul","year":"2024","unstructured":"Gaul C, Gendolla A, Holle D et al (2024) Real-world experience of Erenumab in patients with migraine in Germany: the SPECTRE study. Pain Ther 13(6):1659\u20131678. https:\/\/doi.org\/10.1007\/s40122-024-00658-7","journal-title":"Pain Ther"},{"key":"2259_CR52","doi-asserted-by":"publisher","first-page":"205031212311707","DOI":"10.1177\/20503121231170726","volume":"11","author":"O Hrytsenko","year":"2023","unstructured":"Hrytsenko O, Kopchak O, Kozyk M, Strubchevska K (2023) The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med 11:20503121231170726. https:\/\/doi.org\/10.1177\/20503121231170726","journal-title":"Sage Open Med"},{"issue":"3","key":"2259_CR53","doi-asserted-by":"publisher","first-page":"fcab169","DOI":"10.1093\/braincomms\/fcab169","volume":"3","author":"CH G\u00f6bel","year":"2021","unstructured":"G\u00f6bel CH, Heinze A, Karstedt S et al (2021) Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 3(3):fcab169. https:\/\/doi.org\/10.1093\/braincomms\/fcab169","journal-title":"Brain Commun"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02259-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:36:58Z","timestamp":1781624218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02259-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication was amended to correct misaligned values in Table 1.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the ethics committee of the Ludwig-Maximilians-University Munich (Project No. 19\u2013699). All patients provided their written informed consent before entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have had or are having the following economic or personal ties to the pharmaceutical industry, consulting firms, payers, or healthcare providers: AS is or was member of the following advisory boards: Novartis, Lilly, Sanofi, Allergan, TEVA, and speaker or member of speaker boards on behalf of Novartis, Lilly, Sanofi, Allergan, TEVA. He acted as consultant for Sanofi and TEVA, received grant support for research or education from Novartis and acted as an editorial board member for Lilly, Sanofi and Novartis. GB was or is member of the following advisory boards: Novartis, Lilly, TEVA, Gr\u00fcnenthal, STADA, Organon and speaker or member of following speakers boards: Novartis, Lilly, TEVA, Gr\u00fcnenthal; Consultant: Novartis, Lilly, TEVA, Gr\u00fcnenthal, STADA, Organon; he received grant support for research or education from TEVA. CG is or was member of the following advisory Boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, Merz, Dr. Reddy`s, Vectura Fertin Pharma, Organon and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Reckitt-Benckiser and TEVA. He served in the following editorial boards: Acta Neurologica Scandinavia, Frontiers in Neurology, and Medizinischer Sachverst\u00e4ndiger. XH is an employee of TEVA GmbH. AH is or was member of the following advisory Boards: Abbvie, Hormosan Pharma, Lundbeck, Novartis Pharma and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Hormosan Pharma, Novartis Pharma, Lundbeck, and TEVA. TK is or was member of the following advisory Boards: Allergan, and speaker or member of the following speaker boards: Allergan, TEVA, Lilly, Hormosan. LN was member of the following advisory boards: TEVA, Lilly, Lundbeck, Novartis and Hormosan and speaker or member of the following speakers\u2019 boards: Lilly, Lundbeck, TEVA, Novartis, Abbvie and Hormosan Pharma He received grant support for research from TEVA and Lilly. He served in the editorial boards of Journal of Headache and Pain and Frontiers in Neurology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}